

Coombs, Geoffrey

From: Williams Penny <medicalaffairs@medapharma.com.au>
Sent: Monday, 15 June 2015 8:59 AM
To: info@agargroup.org
Subject: Antibiotic Resistance to clindamycin phosphate and tretinoin

Dear Geoff,

As a brief introduction, I work in Medical Affairs for Meda Pharmaceuticals Australia. We currently have a submission with the TGA for a prescription acne medication which is a topical gel combination containing clindamycin phosphate 1.2% (w/w) and tretinoin 0.025% (w/w). Internationally this combination is known as Ziana®.

We anticipate questions from the TGA regarding our submission relating to potential antibiotic resistance to this product specifically in Australia. We have conducted a comprehensive literature review resulting in limited information about antibiotic resistance to clindamycin phosphate in Australia, and even less regarding the combination with tretinoin.

Having viewed the AGAR website we wonder whether AGAR may have any information/data available that we could tap into or purchase which may be relevant to the TGA regarding potential antibiotic resistance to Ziana in Australia? We expect to receive questions from the TGA at the end of June and will have only a short period in which to respond – we are therefore trying to anticipate the questions and collect as much information as possible in advance.

Please let me know whether the work AGAR conducts is relevant to our enquiry, and if so how best to progress with this? I would be happy to speak with you over the phone if easier (we are in Sydney), please contact me on 0422 002 939 – preferably on a Monday or Wednesday if possible, or please advise your best phone number and a suitable time and I can contact you.

Thank you very much in advance, I look forward to hearing from you.

Best regards
Penny

Penny Williams

Medical Affairs

Meda Pharmaceuticals Pty Ltd

Suite 1, Level 3, 110 Pacific Highway

St Leonards NSW 2065, Australia

E-mail: medicalaffairs@medapharma.com.au

www.meda.com.au

Fax +61 2 9436 4489

Mobile +61 422 002 939

 **Please consider the environment before printing this Email.**

NOTICE: This message contains information which is confidential and may also be privileged. The information may only be used by the intended recipient(s). If you have received this message in error, please notify the sender and remove it from your system.